MIRA PHARMACEUTICALS, INC.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
MIRA$0.62+8.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Number | Description |
|---|---|
| 10.1* | Amendment to Employment Agreement, dated May 13, 2025, between MIRA Pharmaceuticals and Erez Aminov |
| 31.1* | Certification of Chief Executive Officer Pursuant to Sarbanes-Oxley Section 302 |
| 31.2* | Certification of Interim Chief Financial Officer Pursuant to Sarbanes-Oxley Section 302 |
| 32.1** | Certification Pursuant To 18 U.S.C. Section 1350 (*) |
| 32.2** | Certification Pursuant To 18 U.S.C. Section 1350 (*) |
| 101.ins* | Inline XBRL Instance Document |
| 101.sch* | Inline XBRL Taxonomy Extension Schema Document |
| 101.cal* | Inline XBRL Taxonomy Calculation Linkbase Document |
| 101.def* | Inline XBRL Taxonomy Definition Linkbase Document |
| 101.lab* | Inline XBRL Taxonomy Label Linkbase Document |
| 101.pre* | Inline XBRL Taxonomy Presentation Linkbase Document |
| 104* | The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in Inline XBRL. |
| * | Filed herewith. |
| ** | Furnished herewith. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.